Please check your internet connection and try again.
# Diadzein + Genistein + Palmitoylethanolamide
## Overview
This combination product contains diadzein, genistein (isoflavones found in soy), and palmitoylethanolamide (an endogenous fatty acid amide). Their exact therapeutic role and efficacy are not well-established in robust clinical trials for specific medical conditions. They are often marketed as dietary supplements.
## Primary Indications
There are no FDA-approved indications for this combination product. It is often used anecdotally for:
* Pain management (especially chronic or neuropathic pain)
* Inflammation
* Endometriosis-related symptoms
* Menopausal symptom relief
## Adult Dosing
Dosing for this combination is highly variable and lacks standardized recommendations. Typical, but unproven, dosing ranges from:
* **Diadzein/Genistein:** Often found in formulations providing 20-100 mg of total isoflavones daily.
* **Palmitoylethanolamide (PEA):** Commonly dosed between 300-1200 mg once or twice daily.
**Note:** Dosing may depend on the specific product formulation and the intended (though unproven) use.
## Pediatric Dosing
There is no established pediatric dosing for this combination product. Use in pediatric populations is not recommended due to lack of safety and efficacy data.
## Dose Adjustments
No specific dose adjustments are established for renal or hepatic impairment due to lack of pharmacokinetic data.
## Contraindications
* Hypersensitivity to any component of the product.
* Pregnancy and breastfeeding: Safety not established.
## Adverse Effects
Adverse effects are generally mild and infrequent. Potential effects may include:
* Gastrointestinal upset (nausea, bloating)
* Headache
* Allergic reactions
## Key Drug Interactions
* **Hormone-sensitive conditions:** Due to the phytoestrogenic activity of isoflavones, caution is advised in patients with a history of hormone-sensitive cancers (e.g., breast, uterine, ovarian cancer), endometriosis, or uterine fibroids.
* **Anticoagulants/Antiplatelets:** There is theoretical concern for increased bleeding risk, though not well-documented.
* **CYP450 substrates:** Genistein may inhibit certain CYP450 enzymes, potentially affecting the metabolism of drugs metabolized by these pathways. Clinical significance is unclear.
## Monitoring
* Monitor for symptom relief and any adverse effects.
* Patients with a history of hormone-sensitive conditions should discuss use with their healthcare provider.
## Clinical Pearls
* This product is typically classified as a dietary supplement, not a prescription medication.
* Efficacy for specific indications is largely based on anecdotal reports and limited research.
* Patients should be advised that products containing isoflavones can have mild estrogenic effects.
***
*Disclaimer: This information is intended for clinical use and does not substitute for professional medical advice. Always consult the most current prescribing information and guidelines, and individualize therapy based on patient-specific factors.*
